A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response.

Exclusion Criteria

• •Fasting plasma glucose \>220mg/dl at screening.
• •Impaired kidney function, epidermal growth factor receptor of \<60mL/min/1.73m2 at screening.
• •BMI \>40kg/m2.
• •Elevated liver transaminase \> 3 upper limit of normal at screening.
• •Ongoing or recent (i.e. \< 3month) treatment with any oral or injectable glucose-lowering drug other than metformin.
• •Ongoing or recent (i.e. \< 3month) injectable insulin therapy.
• •Ongoing or recent (i.e. \< 3 month) weight loss interventions (e.g. dietary weight loss programs) or any history of bariatric surgery or any documented weight loss \>5% within previous 6 months.
• •Ongoing or recent (i.e. \< 3 month) treatment with anorectic drugs, systemic steroids, medications known to affect gastric motility, or any condition known to affect gastro-intestinal integrity and food absorption.
• •Major medical/surgical event requiring hospitalization in the last 3 months.
• •Known allergy and intolerance to product components or acetaminophen.
• •Alcohol intake higher than 2 servings per day. A serving is 0.4dl of strong alcohols, 1dl of red or white wine, or 3dl of beer.
• •Are unable to comply with protocol procedures in the opinion of the investigator.
• •Have a hierarchical link with the research team members.
• •Positive pregnancy test at screening.
• •Patients who have been dosed in another clinical trial with any investigational drug/new chemical entity within 30 days or 5 half-lives (whichever is longer) prior to screening, or patients currently participating in any investigational trial.
• •Donation of blood or significant amount of blood loss within 8 weeks prior to screening. Patients must also agree to not donate blood within 8 weeks after their last visit.